Antisense oligonucleotides (ASOs) are next-generation drugs that can treat disease by blocking the transfer of harmful messages from our genes.

In people with cancer, ASOs have the potential to block messages that encourage the growth and spread of the tumour.

However, ASOs aren’t used for treating cancer yet.

They must first get delivered inside cancer cells, but the cancer cells won’t let them in.

Finding an effective ASO delivery system is a major challenge.

Cancer cells have gatekeeper molecules that stop unwanted substances from entering.

Although investigators have tried many ways of getting ASOs past the gatekeepers, success has been limited.

Now, in a study recently published in the journal Nucleic Acids Research, researchers from Osaka University have discovered a way to deliver ASOs to their targets inside cancer cells.

The team synthesised a new compound, named L687, which opens specific calcium permeable channels on the surface of cancer cells.

When the calcium flows into cells through the open channels it tells the cells to let in the ASOs.

“We discovered that we could selectively activate the TRPC3/C6 calcium permeable channels1) with the activator L687,” explains lead author Hiroto Kohashi.

“We then found that combination treatment with L687 and ASO promoted efficient uptake of ASO into cancer cells during laboratory tests and tumour cells inside the mouse. As a result, target gene activity was suppressed and ASO efficacy was enhanced.”

Until now, ASOs have mainly been used to treat incurable diseases and had to be delivered into the liver or spinal fluid.

According to the Osaka team’s research, L687 is an effective drug delivery system that may extend the benefits of ASO treatment to other parts of the body.

“We hope that the results of our research will lead to significant progress in the development and delivery of ASOs and similar gene-targeting drugs for treating cancer,” says senior author Masahito Shimojo.

The team believes that L687 could be a particularly effective way of delivering ASO therapy to lung or prostate cancers.

These cancers have many TRPC3/C6 calcium permeable channels1) that can be opened by L687, potentially revealing new targets for these next-generation therapies.

1) TRPC3/C6 channels belong to a Transient Receptor Potential Canonical (TRPC) Channel subfamily of a TRP channel superfamily.

Source: Osaka University